Siegel RL, Miller KD, Jemal A, Cancer statistics. CA Cancer J Clin. 2020;70:7–30.
Akter S, Rahman MA, Hasan MN, Akhter H, Noor P, Islam R, et al. Recent advances in ovarian cancer: therapeutic strategies, potential biomarkers, and technological improvements. Cells. 2022;11:650.
Hu D, Yu J, Feng J, Liu P, Chen JM, Zhang HL, Comparison and trend analysis of cancer incidence in China and globally in 2022. World J Clin Oncol. 2025;16:107016.
Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68:284–296.
Google Scholar
Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14:9–32.
Google Scholar
Bast RC, Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, et al., A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883–7.
Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005;65:2162–9.
Google Scholar
Moore RG, Miller MC, Steinhoff MM, Skates SJ, Lu KH, Lambert-Messerlian G, et al. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am J Obstet Gynecol. 2012;206:e1–8. 351.
Google Scholar
Simon I, Zhuo S, Corral L, Diamandis EP, Sarno MJ, Wolfert RL, et al. B7-h4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res. 2006;66:1570–5.
Google Scholar
Chen F, Shen J, Wang J, Cai P, Huang Y. Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors. Cancer Manag Res. 2018;10:1313–18.
Google Scholar
Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 2010;203:e1–6. 228.
Google Scholar
Fischerova D, Burgetova A. Imaging techniques for the evaluation of ovarian cancer. Best Pr Res Clin Obstet Gynaecol. 2014;28:697–720.
Google Scholar
Khiewvan B, Torigian DA, Emamzadehfard S, Paydary K, Salavati A, Houshmand S, et al. An update on the role of PET/CT and PET/MRI in ovarian cancer. Eur J Nucl Med Mol Imaging. 2017;44:1079–1091.
Google Scholar
Johnson RJ. Radiology in the management of ovarian cancer. Clin Radio. 1993;48:75–82.
Google Scholar
Wolf G, Abolmaali N. Preclinical molecular imaging using PET and MRI. Recent Results Cancer Res. 2013;187:257–310.
Google Scholar
Crestani A, Theodore C, Levaillant JM, Thomassin-Naggara I, Skalli D, Miaihle G, et al. Magnetic resonance and ultrasound fusion imaging to characterise ovarian masses: a feasibility study. Anticancer Res. 2020;40:4115–21.
Google Scholar
Pinto P, Burgetova A, Cibula D, Haldorsen IS, Indrielle-Kelly T, Fischerova D. Prediction of surgical outcome in advanced ovarian cancer by imaging and laparoscopy: a narrative review. Cancers. 2023;15:1904.
van Dam GM, Themelis G, Crane LM, Harlaar NJ, Pleijhuis RG, Kelder W, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nat Med. 2011;17:1315–9.
Google Scholar
Liu Y, Chen S, Sun J, Zhu S, Chen C, Xie W, et al. Folate-targeted and oxygen/indocyanine green loaded lipid nanoparticles for dual-mode imaging and photo-sonodynamic/photothermal therapy of ovarian cancer in vitro and in vivo. Mol Pharm. 2020;17:1442–3.
Google Scholar
Tummers QR, Hoogstins CE, Gaarenstroom KN, de Kroon CD, van Poelgeest MI, Vuyk J, et al. Intraoperative imaging of folate receptor alpha positive ovarian and breast cancer using the tumor specific agent EC17. Oncotarget. 2016;7:32144–55.
Google Scholar
Chang SJ, Bristow RE. Evolution of surgical treatment paradigms for advanced-stage ovarian cancer: redefining ‘optimal’ residual disease. Gynecol Oncol. 2012;125:483–92.
Google Scholar
Committee on the State of the Science in Ovarian Cancer R, Board on Health Care S, Institute of M, National Academies of Sciences E, Medicine, Ovarian Cancers: Evolving Paradigms in Research and Care, National Academies Press (US)Copyright 2016 by the National Academy of Sciences. All rights reserved. Washington (DC), 2016.
Rose M, Burgess JT, O’Byrne K, Richard DJ, Bolderson E. PARP Inhibitors: clinical relevance, mechanisms of action and tumor resistance. Front Cell Dev Biol. 2020;8:564601.
Google Scholar
Lu RM, Hwang YC, Liu IJ, Lee CC, Tsai HZ, Li HJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27:1.
Google Scholar
Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154–64.
Google Scholar
Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20:636–48.
Google Scholar
Gonzalez-Martin A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391–402.
Google Scholar
Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol. 2017;147:267–75.
Google Scholar
Clamp AR, Lorusso D, Oza AM, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. Int J Gynecol Cancer. 2021;31:949–58.
Google Scholar
Oncology ESfM, ESMO 2016 Press release: niraparib significantly improves outcome of ovarian cancer patients in landmark trial. European Society for Medical Oncology, 2016.
Gonzalez-Martin A, Pothuri B, Vergote I, Graybill W, Lorusso D, McCormick CC, et al. Progression-free survival and safety at 3.5years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. Eur J Cancer. 2023;189:112908.
Google Scholar
Sirico M, D’Angelo A, Gianni C, Casadei C, Merloni F, De Giorgi U. Current state and future challenges for PI3K inhibitors in cancer therapy. Cancers. 2023;15:703.
Scott R. Durvalumab combo maintains PFS benefit in ovarian. Cancer Target Therapies Oncol. 2024;13:30.
Dilawari A, Shah M, Ison G, Gittleman H, Fiero MH, Shah A, et al. FDA approval summary: Mirvetuximab Soravtansine-Gynx for FRalpha-positive, platinum-resistant ovarian cancer. Clin Cancer Res. 2023;29:3835–40.
Google Scholar
Bardhan K, Anagnostou T, Boussiotis VA. The PD1:PD-L1/2 pathway from discovery to clinical implementation. Front Immunol. 2016;7:550.
Google Scholar
Peng W, Liu C, Xu C, Lou Y, Chen J, Yang Y, et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res. 2012;72:5209–18.
Google Scholar
Cibula D, Rob L, Mallmann P, Knapp P, Klat J, Chovanec J, et al. Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): a randomized, open-label, phase 2 trial. Gynecol Oncol. 2021;162:652–60.
Google Scholar
Coosemans A, Vanderstraeten A, Tuyaerts S, Verschuere T, Moerman P, Berneman Z, et al. Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma. Anticancer Res. 2013;33:3855–9.
Google Scholar
Li H, Liu Y, Wang Y, Zhao X, Qi X. Hormone therapy for ovarian cancer: emphasis on mechanisms and applications (Review). Oncol Rep. 2021;46:223.
Fields EC, McGuire WP, Lin L, Temkin SM. Radiation treatment in women with ovarian cancer: past, present. Future Front Oncol. 2017;7:177.
Google Scholar
Hatakeyama H, Wu SY, Lyons YA, Pradeep S, Wang W, Huang Q, et al. Role of CTGF in sensitivity to hyperthermia in ovarian and uterine cancers. Cell Rep. 2016;17:1621–31.
Google Scholar
Schumann C, Taratula O, Khalimonchuk O, Palmer AL, Cronk LM, Jones CV, et al. ROS-induced nanotherapeutic approach for ovarian cancer treatment based on the combinatorial effect of photodynamic therapy and DJ-1 gene suppression. Nanomedicine. 2015;11:1961–70.
Google Scholar
Filis P, Mauri D, Markozannes G, Tolia M, Filis N, Tsilidis K. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials. ESMO Open. 2022;7:100586.
Google Scholar
van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378:230–40.
Google Scholar
Wang D, Wang Y, Zhang X, Lv Q, Ma G, Gao Y, et al. A polyoxometalate-encapsulated metal-organic framework nanoplatform for synergistic photothermal-chemotherapy and anti-inflammation of ovarian cancer. Molecules. 2022;27:8350.
Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806–11.
Google Scholar
Quon K, Kassner PD. RNA interference screening for the discovery of oncology targets. Expert Opin Ther Targets. 2009;13:1027–35.
Google Scholar
Raemdonck K, Vandenbroucke RE, Demeester J, Sanders NN, De Smedt SC. Maintaining the silence: reflections on long-term RNAi. Drug Discov Today. 2008;13:917–31.
Google Scholar
Ledford H. Gene-silencing technology gets first drug approval after 20-year wait. Nature. 2018;560:291–92.
Google Scholar
Guo S, Zhang M, Huang Y, Three E. challenges for siRNA drug development. Trends Mol Med. 2024;30:13–24.
Google Scholar
Karim ME, Tha KK, Othman I, Borhan Uddin M, Chowdhury EH. Therapeutic potency of nanoformulations of siRNAs and shRNAs in animal models of cancers. Pharmaceutics. 2018;10:65.
Jackson AL, Linsley PS. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov. 2010;9:57–67.
Google Scholar
Bumcrot D, Manoharan M, Koteliansky V, Sah DW. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat Chem Biol. 2006;2:711–9.
Google Scholar
Juliano R, Bauman J, Kang H, Ming X. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol Pharm. 2009;6:686–95.
Google Scholar
Caillaud M, El Madani M, Massaad-Massade L. Small interfering RNA from the lab discovery to patients’ recovery. J Control Release. 2020;321:616–28.
Google Scholar
Dominska M, Dykxhoorn DM. Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci 123. 2010;8:1183–9.
Google Scholar
Fernandes F, Kotharkar P, Chakravorty A, Kowshik M, Talukdar I. Nanocarrier Mediated siRNA Delivery Targeting Stem Cell Differentiation. Curr Stem Cell Res Ther. 2020;15:155–72.
Google Scholar
Hu B, Zhong L, Weng Y, Peng L, Huang Y, Zhao Y, et al. Therapeutic siRNA: state of the art. Signal Transduct Target Ther. 2020;5:101.
Google Scholar
Watts JK, Deleavey GF, Damha MJ. Chemically modified siRNA: tools and applications. Drug Discov Today. 2008;13:842–55.
Google Scholar
Khvorova A, Watts JK. The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol. 2017;35:238–48.
Google Scholar
Jahan S, Karim ME, Chowdhury EH. Nanoparticles targeting receptors on breast cancer for efficient delivery of chemotherapeutics. Biomedicines. 2021;9:114.
Tomalia DA. In quest of a systematic framework for unifying and defining nanoscience. J Nanopart Res. 2009;11:1251–310.
Google Scholar
Yang EY, Shah K. Nanobodies: next generation of cancer diagnostics and therapeutics. Front Oncol. 2020;10:1182.
Google Scholar
Nag K, Sarker MEH, Kumar S, Khan H, Chakraborty S, Islam MJ, et al. DoE-derived continuous and robust process for manufacturing of pharmaceutical-grade wide-range LNPs for RNA-vaccine/drug delivery. Sci Rep. 2022;12:9394.
Google Scholar
Hassett KJ, Higgins J, Woods A, Levy B, Xia Y, Hsiao CJ, et al. Impact of lipid nanoparticle size on mRNA vaccine immunogenicity. J Control Release. 2021;335:237–46.
Google Scholar
Xu Y, Szoka FC Jr. Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. Biochemistry. 1996;35:5616–23.
Google Scholar
Yadav K, Singh D, Singh MR, Pradhan M. Multifaceted targeting of cationic liposomes via co-delivery of anti-IL-17 siRNA and corticosteroid for topical treatment of psoriasis. Med Hypotheses. 2020;145:110322.
Google Scholar
Zhao YN, Piao YZ, Zhang CM, Jiang YM, Liu A, Cui SH, et al. Replacement of quaternary ammonium headgroups by tri-ornithine in cationic lipids for the improvement of gene delivery in vitro and in vivo. J Mater Chem B. 2017;5:7963–73.
Google Scholar
Zhang XX, Lamanna CM, Kohman RE, McIntosh TJ, Han X, Grinstaff MW, et al. siRNA transfection efficiency depends on peptide headgroup. Soft Matter. 2013;9:C3SM27633C.
Zhang MM, Bahal R, Rasmussen TP, Manautou JE, Zhong XB. The growth of siRNA-based therapeutics: updated clinical studies. Biochem Pharm. 2021;189:114432.
Google Scholar
Yang X, Iyer AK, Singh A, Choy E, Hornicek FJ, Amiji MM, et al. MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer. Sci Rep. 2015;5:8509.
Google Scholar
Zhao G, Liu A, Zhang Y, Zuo ZQ, Cao ZT, Zhang HB, et al. Nanoparticle-delivered siRNA targeting Bruton’s tyrosine kinase for rheumatoid arthritis therapy. Biomater Sci. 2019;7:4698–707.
Google Scholar
Zhou J, Liu Z, Li F. Upconversion nanophosphors for small-animal imaging. Chem Soc Rev. 2012;41:1323–49.
Google Scholar
Saha K, Agasti SS, Kim C, Li X, Rotello VM. Gold nanoparticles in chemical and biological sensing. Chem Rev. 2012;112:2739–79.
Google Scholar
Lu AH, Salabas EL, Schuth F. Magnetic nanoparticles: synthesis, protection, functionalization, and application, Angew. Chem Int Ed Engl. 2007;46:1222–44.
Google Scholar
Wang F, Liu X. Recent advances in the chemistry of lanthanide-doped upconversion nanocrystals. Chem Soc Rev. 2009;38:976–89.
Google Scholar
Lan K, Zhao D. Functional ordered mesoporous materials: present and future. Nano Lett. 2022;22:3177–3179.
Google Scholar
Wang J, Fan X, Han X, Lv K, Zhao Y, Zhao Z, et al. Ultrasmall inorganic mesoporous nanoparticles: preparation, functionalization, and application. Adv Mater. 2024;36:e2312374.
Google Scholar
Dalmina M, Pittella F, Sierra JA, Souza GRR, Silva AH, Pasa AA, et al. Magnetically responsive hybrid nanoparticles for in vitro siRNA delivery to breast cancer cells. Mater Sci Eng C Mater Biol Appl. 2019;99:1182–90.
Google Scholar
Tu J, Wang T, Shi W, Wu G, Tian X, Wang Y, et al. Multifunctional ZnPc-loaded mesoporous silica nanoparticles for enhancement of photodynamic therapy efficacy by endolysosomal escape. Biomaterials. 2012;33:7903–14.
Google Scholar
Ma D, Shen H, Chen F, Liu W, Zhao Y, Xiao Z, et al. Inflammatory microenvironment-responsive nanomaterials promote spinal cord injury repair by targeting IRF5, Adv Healthc. Mater. 2022;11:e2201319.
Caldwell JD, Vurgaftman I, Tischler JG, Glembocki OJ, Owrutsky JC, Reinecke TL. Atomic-scale photonic hybrids for mid-infrared and terahertz nanophotonics. Nat Nanotechnol. 2016;11:9–15.
Google Scholar
Wang Q, Xiao J, Su YH, Huang JW, Li JH, Qiu LG, et al. Fabrication of thermoresponsive magnetic micelles from amphiphilic poly(phenyl isocyanide) and FeO nanoparticles for controlled drug release and synergistic thermochemotherapy. Polym Chem-Uk. 2021;12:2132–40.
Google Scholar
Siragusa G, Tomasello L, Giordano C, Pizzolanti G. Survivin (BIRC5): implications in cancer therapy. Life Sci. 2024;350:122788.
Google Scholar
Zhang Y, Huang H, Fu H, Zhao M, Wu Z, Dong Y, et al. Dual-mode US/MRI nanoparticles delivering siRNA and Pt(iv) for ovarian cancer treatment. RSC Adv. 2019;9:33302–9.
Google Scholar
Boehnke N, Correa S, Hao L, Wang W, Straehla JP, Bhatia SN, et al. Theranostic layer-by-layer nanoparticles for simultaneous tumor detection and gene silencing, angew. Chem Int Ed Engl. 2020;59:2776–83.
Google Scholar
Liu Y, Long T, Zhang N, Qiao B, Yang Q, Luo Y, et al. Ultrasound-mediated long-circulating nanopolymer delivery of therapeutic siRNA and antisense microrNAs leads to enhanced paclitaxel sensitivity in epithelial ovarian cancer chemotherapy. ACS Biomater Sci Eng. 2020;6:4036–50.
Google Scholar
Hu D, Du J, Xing Y, Cheng Y, He R, Liang X, et al. SIK2: a critical glucolipid metabolic reprogramming regulator and potential target in ovarian cancer. J Obstet Gynaecol Res. 2023;49:2000–9.
Google Scholar
Lee M, Hwang J, Song Y, Kim S, Park N. Anti-miR21-conjugated DNA nanohydrogel for enhanced cancer therapy. Biomater Adv. 2025;169:214160.
Google Scholar
VandenHeuvel SN, Chau E, Mohapatra A, Dabbiru S, Roy S, O’Connell C, et al. Macrophage checkpoint nanoimmunotherapy has the potential to reduce malignant progression in bioengineered in vitro models of ovarian. Cancer, ACS Appl Bio Mater. 2024;7:7871–82.
Google Scholar
Hao L, Boehnke N, Elledge SK, Harzallah NS, Zhao RT, Cai E, et al. Targeting and monitoring ovarian cancer invasion with an RNAi and peptide delivery system. Proc Natl Acad Sci USA. 2024;121:e2307802121.
Google Scholar
Inoue T, Ishihara R. Photodynamic therapy for esophageal cancer. Clin Endosc. 2021;54:494–8.
Google Scholar
Zhang R, Wu C, Tong L, Tang B, Xu QH. Multifunctional core-shell nanoparticles as highly efficient imaging and photosensitizing agents. Langmuir. 2009;25:10153–8.
Google Scholar
Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer. 2003;3:380–7.
Google Scholar
Yanovsky RL, Bartenstein DW, Rogers GS, Isakoff SJ, Chen ST. Photodynamic therapy for solid tumors: a review of the literature. Photodermatol Photoimmunol Photomed. 2019;35:295–303.
Google Scholar
Shi X, Zhang CY, Gao J, Wang Z. Recent advances in photodynamic therapy for cancer and infectious diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019;11:e1560.
Google Scholar
Dai J, Cheng Y, Wu J, Wang Q, Wang W, Yang J, et al. Modular peptide probe for pre/intra/postoperative therapeutic to reduce recurrence in ovarian cancer. ACS Nano. 2020;14:14698–714.
Google Scholar
Cao J, Lou S, Ying M, Yang B. DJ-1 as a human oncogene and potential therapeutic target. Biochem Pharm. 2015;93:241–50.
Google Scholar
Wan Y, Fu LH, Li C, Lin J, Huang P. Conquering the hypoxia limitation for photodynamic therapy. Adv Mater. 2021;33:e2103978.
Google Scholar
Nath S, Saad MA, Pigula M, Swain JWR, Hasan T. Photoimmunotherapy of ovarian cancer: a unique niche in the management of advanced disease. Cancers. 2019;11:1887.
Wust P, Hildebrandt B, Sreenivasa G, Rau B, Gellermann J, Riess H, et al. Hyperthermia in combined treatment of cancer. Lancet Oncol. 2002;3:487–97.
Google Scholar
van der Zee J. Heating the patient: a promising approach? Ann Oncol. 2002;13:1173–84.
Google Scholar
Zhang GP, Xie ZL, Jiang J, Zhao YT, Lei K, Lin ZL, et al. Mechanical confinement promotes heat resistance of hepatocellular carcinoma via SP1/IL4I1/AHR axis. Cell Rep Med. 2023;4:101128.
Google Scholar
Wu J, Wang Q, Dong X, Xu M, Yang J, Yi X, et al. Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer. Theranostics. 2021;11:3710–24.
Google Scholar
Ghareghomi S, Ahmadian S, Zarghami N, Hemmati S. hTERT-molecular targeted therapy of ovarian cancer cells via folate-functionalized PLGA nanoparticles co-loaded with MNPs/siRNA/wortmannin. Life Sci. 2021;277:119621.
Google Scholar
Dong R, Najjar G, Günes C, Lechel A. Aberrant TERT expression: linking chronic inflammation to hepatocellular carcinoma(†). J Pathol. 2025;266:130–133.
Google Scholar
Jagadeesh S, Banerjee PP. Inositol hexaphosphate represses telomerase activity and translocates TERT from the nucleus in mouse and human prostate cancer cells via the deactivation of AKT and PKCalpha. Biochem Biophys Res Commun. 2006;349:1361–7.
Google Scholar
Ihara M, Shichijo K, Takeshita S, Kudo T. Wortmannin, a specific inhibitor of phosphatidylinositol-3-kinase, induces accumulation of DNA double-strand breaks. J Radiat Res. 2020;61:171–6.
Google Scholar
Bani N, Rahmani F, Shakour N, Amerizadeh F, Khalili-Tanha G, Khazaei M, et al. Wortmannin inhibits cell growth and induces apoptosis in colorectal cancer cells by suppressing the PI3K/AKT pathway. Anti-Cancer Agents Med Chem. 2024;24:916–27.
Google Scholar
Duan C, Gao Y, Luan S, Guo S, Cao X, Xu P, et al. Noninvasive evaluation of HABP1 expression with (99m)Tc-labeled small-interference RNA in ovarian cancer. Int J Radiat Biol. 2021;97:1569–77.
Google Scholar
Singh MS, Ramishetti S, Landesman-Milo D, Goldsmith M, Chatterjee S, Palakuri R, et al. Therapeutic gene silencing using targeted lipid nanoparticles in metastatic ovarian cancer. Small. 2021;17:e2100287.
Google Scholar
Hao L, Wang JM, Liu BQ, Yan J, Li C, Jiang JY, et al. m6A-YTHDF1-mediated TRIM29 upregulation facilitates the stem cell-like phenotype of cisplatin-resistant ovarian cancer cells. Biochim Biophys Acta Mol Cell Res. 2021;1868:118878.
Google Scholar
Chen L, Luo J, Zhang J, Wang S, Sun Y, Liu Q, et al. Dual targeted nanoparticles for the codelivery of doxorubicin and siRNA cocktails to overcome ovarian cancer stem cells. Int J Mol Sci. 2023;24:11575.
Samykutty A, Grizzle WE, Fouts BL, McNally MW, Chuong P, Thomas A, et al. Optoacoustic imaging identifies ovarian cancer using a microenvironment targeted theranostic wormhole mesoporous silica nanoparticle. Biomaterials. 2018;182:114–26.
Google Scholar
Xu M, Qi Y, Liu G, Song Y, Jiang X, Du B. Size-dependent in vivo transport of nanoparticles: implications for delivery, targeting, and clearance. ACS Nano. 2023;17:20825–49.
Google Scholar
Qiu C, Han HH, Sun J, Zhang HT, Wei W, Cui SH, et al. Regulating intracellular fate of siRNA by endoplasmic reticulum membrane-decorated hybrid nanoplexes. Nat Commun. 2019;10:2702.
Google Scholar
Farra R, Maruna M, Perrone F, Grassi M, Benedetti F, Maddaloni M, et al. Strategies for delivery of sirnas to ovarian cancer cells. Pharmaceutics. 2019;11:547.
Hattab D, Gazzali AM, Bakhtiar A. Clinical advances of siRNA-based nanotherapeutics for cancer treatment. Pharmaceutics. 2021;13:1009.
Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1:16014.
Google Scholar
Ashrafizadeh M, Zarrabi A, Hushmandi K, Hashemi F, Rahmani Moghadam E, Raei M, et al. Progress in natural compounds/siRNA co-delivery employing nanovehicles for cancer therapy. ACS Combinatorial Sci. 2020;22:669–700.
Google Scholar
Goyal R, Chopra H, Singh I, Dua K, Gautam RK. Insights on prospects of nano-siRNA based approaches in treatment of Cancer. Front Pharmacol. 2022;13:985670.
Google Scholar
Foulkes R, Man E, Thind J, Yeung S, Joy A, Hoskins C. The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives. Biomater Sci. 2020;8:4653–64.
Google Scholar
Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33:941–51.
Google Scholar
Chen S, Tam YYC, Lin PJC, Sung MMH, Tam YK, Cullis PR. Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA. J Control Release. 2016;235:236–44.
Google Scholar
Truong NP, Whittaker MR, Mak CW, Davis TP. The importance of nanoparticle shape in cancer drug delivery. Expert Opin Drug Deliv. 2015;12:129–42.
Google Scholar
Wang Z, Wu Z, Liu J, Zhang W. Particle morphology: an important factor affecting drug delivery by nanocarriers into solid tumors. Expert Opin Drug Deliv. 2018;15:379–95.
Google Scholar
Wen R, Umeano AC, Chen P, Farooqi AA. Polymer-based drug delivery systems for cancer. Crit Rev Ther Drug Carr Syst. 2018;35:521–53.
Google Scholar
Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem Rev. 2016;116:2602–63.
Google Scholar
He C, Yue H, Xu L, Liu Y, Song Y, Tang C, et al. siRNA release kinetics from polymeric nanoparticles correlate with RNAi efficiency and inflammation therapy via oral delivery. Acta Biomater. 2020;103:213–22.
Google Scholar
Matsui H, Sato Y, Hatakeyama H, Akita H, Harashima H. Size-dependent specific targeting and efficient gene silencing in peritoneal macrophages using a pH-sensitive cationic liposomal siRNA carrier. Int J Pharm. 2015;495:171–8.
Google Scholar
Nagao S, Fujiwara K, Yamamoto K, Tanabe H, Okamoto A, Takehara K, et al. Intraperitoneal carboplatin for ovarian cancer – a phase 2/3 trial. NEJM Evid. 2023;2:EVIDoa2200225.
Google Scholar
Climent MT, Serra A, Balaguer C, Llueca A. Should we abandon intraperitoneal chemotherapy in the treatment of advanced ovarian cancer? A meta-analysis. J Pers Med. 2023;13:1636.
Hasegawa K, Shimada M, Takeuchi S, Fujiwara H, Imai Y, Iwasa N, et al. A phase 2 study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in front-line treatment of suboptimal residual ovarian cancer. Br J Cancer. 2020;122:766–70.
Google Scholar
Zhan T, Song W, Jing G, Yuan Y, Kang N, Zhang Q. Zebrafish live imaging: a strong weapon in anticancer drug discovery and development. Clin Transl Oncol. 2024;26:1807–35.
Google Scholar
Monk BJ, Chan JK, Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer? Ann Oncol. 2017;28:40–5.
Kumar KP, Madhusoodanan M, Pangath M, Menon D. Innovative landscapes in intraperitoneal therapy of ovarian cancer. Drug Deliv Transl Res. 2025;15:1877–906.
Google Scholar
Sugarbaker PH. Optimizing regional chemotherapy for epithelial ovarian cancer. J Obstet Gynaecol Res. 2022;48:1306–17.
Google Scholar
Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol. 2005;23:457–62.
Google Scholar
Meng Z, Lu M, RNA interference-induced innate immunity, off-target effect, or immune adjuvant? Front Immunol. 2017;8:331.
Kalola UK, Pellegrini MV, Patisiran, StatPearls, 2025.
Barroso A, Estevinho F, Hespanhol V, Teixeira E, Ramalho-Carvalho J, Araujo A. Management of infusion-related reactions in cancer therapy: strategies and challenges. ESMO Open. 2024;9:102922.
Google Scholar
McSweeney MD, Price LSL, Wessler T, Ciociola EC, Herity LB, Piscitelli JA, et al. Overcoming anti-PEG antibody mediated accelerated blood clearance of pegylated liposomes by pre-infusion with high molecular weight free PEG. J Control Release. 2019;312:138–46.
Google Scholar
Carvalho AM, Cordeiro RA, Faneca H. Silica-based gene delivery systems: from design to therapeutic applications. Pharmaceutics. 2020;12:649.
Li X, Li J, Wei J, Du W, Su C, Shen X, et al. Design strategies for novel lipid nanoparticle for mRNA vaccine and therapeutics: current understandings and future perspectives. MedComm. 2025;6:e70414.
Google Scholar
Johnson ME, Shon J, Guan BM, Patterson JP, Oldenhuis NJ, Eldredge AC, et al. Fluorocarbon modified low-molecular-weight polyethylenimine for siRNA delivery. Bioconjug Chem. 2016;27:1784–8.
Google Scholar
Xue L, Yan Y, Kos P, Chen X, Siegwart DJ. PEI fluorination reduces toxicity and promotes liver-targeted siRNA delivery. Drug Deliv Transl Res. 2021;11:255–60.
Google Scholar
Sanati M, Figueroa-Espada CG, Han EL, Mitchell MJ, Yavari SA. Bioengineered nanomaterials for siRNA therapy of chemoresistant cancers. ACS Nano. 2024;18:34425–34463.
Google Scholar
Wu QX, De Isla N, Zhang L. Biomaterial-based nucleic acid delivery systems for in situ tissue engineering and regenerative medicine. Int J Mol Sci. 2025;26:7384.
Yajun Xu JC, Ding Jianxun, Sun Jing, Song Wantong, Tang Zhaohui, Xiao Chunsheng. Synthetic polymers for drug, gene, and vaccine delivery. Polym Sci Technol. 2025;1:171–220.
Google Scholar
Han X, Zhang H, Butowska K, Swingle KL, Alameh MG, Weissman D, et al. An ionizable lipid toolbox for RNA delivery. Nat Commun. 2021;12:7233.
Google Scholar
Auerbach M Advances in ionizable lipid design: accelerating mRNA therapeutic development through rapid optimization platforms. Am Pharmaceutical Rev. 2025;23:1002–8.
Zuckerman JE, Gritli I, Tolcher A, Heidel JD, Lim D, Morgan R, et al. Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA. Proc Natl Acad Sci USA. 2014;111:11449–54.
Google Scholar
Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013;3:406–17.
Google Scholar
Strumberg D, Schultheis B, Traugott U, Vank C, Santel A, Keil O, et al. Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. Int J Clin Pharmacol Therapeutics. 2012;50:76–8.
Google Scholar
Landen CN Jr., Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005;65:6910–8.
Google Scholar
Belhadj Z, He B, Fu J, Zhang H, Wang X, Dai W, et al. Regulating Interactions between targeted nanocarriers and mononuclear phagocyte system via an esomeprazole-based preconditioning strategy. Int J Nanomed. 2020;15:6385–6399.
Google Scholar
Wayne EC, Long C, Haney MJ, Batrakova EV, Leisner TM, Parise LV, et al. Targeted delivery of siRNA lipoplexes to cancer cells using macrophage transient horizontal gene transfer. Adv Sci. 2019;6:1900582.
Google Scholar
